Upcoming Post-Conference Perspectives: ASH 2021

Teclistamab shows promising real-world effectiveness and safety in older adults with relapsed/refractory multiple myeloma (R/R MM), matching clinical trial outcomes.

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

Investigators believe the SWIFT-seq system holds potential to replace more invasive bone marrow biopsies.

Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in NDMM.

Past efforts to collect data and to understand the relationship between minimal residual disease and outcomes will help researchers in multiple myeloma develop a new generation of targeted therapies, decide when treatment can be stopped, and possibly screen populations for the disease.

Early identification of multiple myeloma could help clinicians intervene more swiftly.